184 related articles for article (PubMed ID: 16315929)
21. [A new regimen for TS-1 therapy designed to minimize adverse reactions by introducing a one-week interval after each two-week dosing session].
Kimura Y; Kikkawa N; Iijima S; Kato T; Naoi Y; Hayashi T; Tanigawa T; Yamamoto H; Kurokawa E
Gan To Kagaku Ryoho; 2002 Aug; 29(8):1403-9. PubMed ID: 12214468
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacokinetics and adverse event of TS-1 administered through gastrostomy].
Hirano K; Nakamura K; Hasegawa M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):859-62. PubMed ID: 15984532
[TBL] [Abstract][Full Text] [Related]
23. [A case of CA19-9 producing gastric cancer treated by low-dose administration of TS-1 for adjuvant chemotherapy].
Takashima I; Seto Y; Nagamine I; Kegoya Y; Kodoi A; Nakayama H
Gan To Kagaku Ryoho; 2005 Apr; 32(4):503-5. PubMed ID: 15853217
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured.
Ando Y; Kawada K; Inada M; Morita S; Mitsuma A; Yasuda Y; Hiramatsu M; Fujimoto Y; Fujita K
Oncology; 2012; 83(1):38-44. PubMed ID: 22722580
[TBL] [Abstract][Full Text] [Related]
25. [A case report of adjuvant chemotherapy (TS-1) for far advanced gastric cancer in which the patient maintained a good quality of life].
Omoto Y; Sekiguchi C; Hyodo M; Ohdaira T; Kumano H; Ohtuka S
Gan To Kagaku Ryoho; 2003 Mar; 30(3):399-402. PubMed ID: 12669400
[TBL] [Abstract][Full Text] [Related]
26. [A case of advanced gastric cancer with bone metastases and DIC responding to oral administration of TS-1].
Omatsu T; Ichikawa H; Kawahito Y; Ashihara E; Yamamoto A; Kadoya M; Takegami T; Takanashi Y; Naito Y; Yoshida N; Sugino S; Yoshikawa T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):869-73. PubMed ID: 12852359
[TBL] [Abstract][Full Text] [Related]
27. [Effective use of TS-1 in a case of advanced gastric cancer, both in treating the tumor and in maintaining the patient's quality of life].
Shiroko J; Goto N; Yoshimura K; Oonishi T; Nakai M; Asano H; Ukita M; Tanabashi S; Kametani M
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1829-33. PubMed ID: 12402438
[TBL] [Abstract][Full Text] [Related]
28. [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1].
Mikami Y; Tsukuda M; Kawai S; Kagesato Y; Tanigaki Y; Horiuchi C; Mochimatsu I
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1473-7. PubMed ID: 14584280
[TBL] [Abstract][Full Text] [Related]
29. [Every-other-day TS-1 administration for recurrent or non-curative advanced gastric carcinoma].
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Saito S; Kurasina K; Aoki T; Yasuda Y; Nagai H; Tamada K
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1651-5. PubMed ID: 12355955
[TBL] [Abstract][Full Text] [Related]
30. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
[TBL] [Abstract][Full Text] [Related]
31. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
Matsumoto H; Hirai T; Hirabayashi Y; Murakami H; Higashida M; Kawabe Y; Fuchimoto M; Fujikura H; Hato S; Urakami A; Yamashita K; Tsunoda T
Gan To Kagaku Ryoho; 2007 Jun; 34(6):869-73. PubMed ID: 17565248
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
[TBL] [Abstract][Full Text] [Related]
34. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T; Taguchi T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
[TBL] [Abstract][Full Text] [Related]
35. Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts.
Takahashi I; Emi Y; Kakeji Y; Uchida J; Fukushima M; Maehara Y
Oncology; 2005; 68(2-3):130-7. PubMed ID: 16006750
[TBL] [Abstract][Full Text] [Related]
36. [A case of N3 gastric cancer successfully treated by TS-1 followed by curative resection].
Yoshida K; Ishikawa H; Sumida Y; Hara S; Kondou M; Hashizume S; Tokunaga T; Kamohara R; Minami H; Iwasaki K
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1321-3. PubMed ID: 16969034
[TBL] [Abstract][Full Text] [Related]
37. [Adjuvant chemotherapy with TS-1 for head and neck cancer--side effect of two-week application followed by one-week rest regimen].
Itoi A; Takashima M; Ishimasa H; Murata H; Tomoda K
Gan To Kagaku Ryoho; 2006 May; 33(5):617-20. PubMed ID: 16685159
[TBL] [Abstract][Full Text] [Related]
38. [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Hara A; Tokuhara T; Takahashi Y; Izumi N; Iwamoto S; Satake K
Gan To Kagaku Ryoho; 2004 Apr; 31(4):601-4. PubMed ID: 15114708
[TBL] [Abstract][Full Text] [Related]
39. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients.
Kochi M; Fujii M; Kanamori N; Kaiga T; Aizaki K; Takahashi T; Takayama T
Cancer Chemother Pharmacol; 2007 Oct; 60(5):693-701. PubMed ID: 17690883
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of TS-1 in patients with peritonitis carcinomatosa from gastric cancer].
Nakagawa A; Ichiki M; Sai K; Sugawara H
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1501-3. PubMed ID: 14584285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
